Log In
BCIQ
Print this Print this
 

diacerein (AC-203, CCP-020)

  Manage Alerts
Collapse Summary General Information
Company TWi Pharmaceuticals Holding Inc.
DescriptionTopical formulation of diacerein, a small molecule inhibitor of caspase-1 (CASP1) and interleukin-1 (IL-1) beta
Molecular Target Caspase-1 (CASP1) ; Interleukin-1 (IL-1) beta
Mechanism of Action 
Therapeutic ModalitySmall molecule
Latest Stage of DevelopmentPhase II
Standard IndicationBlistering disorder
Indication DetailsTreat epidermolysis bullosa
Regulatory Designation U.S. - Orphan Drug (Treat epidermolysis bullosa)
PartnerCastle Creek Pharmaceuticals LLC

 Product Details
 Archive Items are loading loading
Collapse Summary Deals Information
Total Number of DealsTotal Deal ValueTotal Upfront CashTotal Milestone Payments

1

0

0

0


 Deals Details
DateCompanies InvolvedDeal HeadlineTotal Deal ValueTotal Upfront CashTotal Milestone

12/17/2015

Undisclosed

Undisclosed

Undisclosed

Get a free BioCentury trial today